Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089050 · ClinicalTrials.gov registry record · Phase 2
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00089050: Completed Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
NCT00089050 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089050, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells more sensitive to the drug. Combining gemtuzumab ozogamicin with cyclosporine may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemtuzumab ozogamicin together with cyclosporine works in treating older patients with relapsed acute myeloid leukemia.
Interventions
- DRUG cyclosporine
- DRUG gemtuzumab ozogamicin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00089050 record still lists
NCT00089050 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT00089050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089050 about?
NCT00089050 is a clinical study titled "Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia". RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Cyclosporine may increase the effectiveness of gemtuzumab ozogamicin by making cancer cells more sensitive to the dru...
What is the current status of trial NCT00089050?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00089050?
The interventions under investigation include: cyclosporine (DRUG), gemtuzumab ozogamicin (DRUG).
Who is sponsoring clinical trial NCT00089050?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia